Department of NeuroOncology, Moffitt Cancer Center, Tampa, FL, 33612, USA.
Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA.
J Neurooncol. 2021 Feb;151(3):367-373. doi: 10.1007/s11060-020-03438-3. Epub 2021 Feb 21.
Most clinical trials in neurooncology are led by investigators primarily trained in neurology or medical oncology. While neurosurgeons are trained to be problem-solvers and innovators, research training has historically been focused on laboratory-based discovery approaches and formalized training in prospective clinical trials research is not part of routine graduate training.
We reviewed literature that demonstrates that innovation and problem-solving are integral to the practice of neurosurgery cite multiple examples of advances in technique and technology that may have had an empirical origin but that led to prospective clinical trials resulting in change in practice.
Neurosurgeons have developed and led both traditional (clinical outcome-oriented) and translational prospective clinical trials that have evaluated the best use of currently available therapeutics or tested the ability of novel therapeutics to alter the biology and/or course of disease.
In this review, we focus on a number of the recently developed technologies and therapeutics that were evaluated in clinical trials led or co-led by neurosurgeons. We also highlight some of the barriers that need to be addressed in order to foster neurosurgical participation and leadership in the prospective development of novel therapeutics.
大多数神经肿瘤学临床试验都是由主要接受神经病学或肿瘤医学培训的研究人员领导的。虽然神经外科医生被训练成为解决问题和创新者,但研究培训历史上一直侧重于基于实验室的发现方法,并且正式的前瞻性临床试验研究培训不是常规研究生培训的一部分。
我们回顾了文献,证明创新和解决问题是神经外科实践的重要组成部分,引用了多个技术和技术进步的例子,这些例子可能具有经验来源,但导致了前瞻性临床试验,从而改变了实践。
神经外科医生开发并领导了传统的(以临床结果为导向)和转化的前瞻性临床试验,这些试验评估了目前可用治疗方法的最佳使用,或测试了新型治疗方法改变生物学和/或疾病进程的能力。
在本次综述中,我们重点关注了一些由神经外科医生领导或共同领导的临床试验中评估的最近开发的技术和治疗方法。我们还强调了为促进神经外科参与和领导新型治疗方法的前瞻性开发而需要解决的一些障碍。